COVID-19 Vaccine (Vero Cell), Inactivated
Sponsors
Jiangsu Rec-Biotechnology Co., Ltd., Sinovac Research and Development Co., Ltd., China National Biotec Group Company Limited, Sinovac Life Sciences Co., Ltd., Sinovac Biotech (Colombia) S.A.S.
Conditions
COVID-19SARS-CoV-2 Infection
Phase 2
Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)
CompletedNCT05323435
Start: 2022-05-30End: 2023-01-16Updated: 2023-04-25
Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
CompletedNCT05463354
Start: 2022-07-11End: 2024-01-26Updated: 2024-04-24
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster
WithdrawnNCT05465902
Start: 2023-07-07End: 2024-12-31Updated: 2025-03-28
Phase 3
Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above
NCT05374954
Start: 2022-05-10End: 2023-11-10Updated: 2023-06-18
Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above
NCT05382871
Start: 2022-05-27End: 2024-03-31Updated: 2023-06-18
Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated
NCT05433272
Start: 2023-08-10End: 2023-09-10Target: 1400Updated: 2023-01-12
Phase 4
Unknown Phase
Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose
NCT05367895
Start: 2022-07-30End: 2023-02-15Target: 14000Updated: 2023-01-12
A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
CompletedNCT06381843
Start: 2022-08-02End: 2023-12-30Updated: 2024-04-25